 | This article has not yet been rated on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
CURRENT CONTENT Vifor Pharma – formerly the Galenica Group[1] – is a Swiss global specialty pharmaceutical company.[2]
PROPOSED CONTENT Vifor Pharma Group is a global specialty pharmaceuticals company and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in Switzerland.
Vifor Pharma is active in the treatment of iron deficiency and iron deficiency anaemia. [i] The Group also has a focus on the management of conditions in nephrology, cardiology and rare diseases.
In 2017, Vifor Pharma Group was listed (ticker symbol VIFN) on the Swiss Stock Exchange (SIX) after splitting up the former Galenica Group. This was completed through an initial public offering (IPO) of Galenica Santé (listed as GALE).
Vifor Pharma Group is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA).[iii]
Side bar:
CURRENT CONTENT: • No photo • Type: Aktiengesellschaft • ISIN: CH0364749348 • Industry: Pharmaceutics • Founded: 2008 • Headquarters: Glattbrugg, Switzerland • Key people: Etienne Jornod (Chairman) • Revenue: 1'585 million CHF (2018) • Number of employees: 2,650 (50% in Switzerland) (2017) • Website: www.viforpharma.com
PROPOSED CONTENT • Vifor Pharma HQ photo • Type: Public, Aktiengesellschaft • Traded as: SIX: VIFN • ISIN: CH0364749348 • Industry: Pharmaceutical • Founded: 1933 • Headquarters: Switzerland • Areas served: Worldwide • Products: See list [hyperlink to products section] • Key People: Etienne Jornod (Executive Chairman), Stefan Schulze (COO), Colin Bond (CFO)[iii] • Net sales: 1,584.6 million CHF (2018) [ii] • Gross profit: 1,000.5 million CHF (2018) [ii] • EBITDA: 391.5 million CHF (2018) • Operating profit (EBIT): 227.4 million CHF (2018) [ii] • Website: www.viforpharma.com
General information
CURRENT CONTENT The Vifor Pharma Group - part of the former Galenica Group - is a global specialty pharmaceutical company[2] focusing on three areas: iron deficiency, nephrology and cardiorenal therapies.[3]
PROPOSED CONTENT
Structure and operations
Vifor Pharma Group is present in North and South America, Europe, the Middle East and Asia Pacific and works with over 100 partners all around the world.
Vifor Pharma Group develops, manufactures and markets pharmaceutical products including prescription and non-prescription products. The Group’s businesses include:
• Vifor Pharma – focused on iron deficiency and iron deficiency anaemia. The product portfolio includes: o Ferinject® / Injectafer® (ferric carboxymaltose) o Venofer® (iron sucrose) o Maltofer® (iron polymaltose)
• Vifor Fresenius Medical Care Renal Pharma (VFMCRP) – focused on kidney disease patients, including anaemia, mineral and bone management, cardio-renal conditions, and rare diseases. The product portfolio includes: o Mircera® (methoxy polyethylene glycol-epoetin beta), anaemia o Velphoro® (polynuclear iron (III)-oxyhydroxide, sucroferric oxyhydroxide), mineral and bone management o Rayaldee® (calcifediol), mineral and bone management o OsvaRen® (calcium acetate and magnesium carbonate), mineral and bone management o Veltassa® (patiromer), cardio-renal conditions, specifically hyperkalaemia
• OM Pharma – focused on infectious diseases and the immune system. The product portfolio includes: o Broncho-Vaxom® (bacterial lysate medicines), recurrent respiratory tract infections o Dicynone® (Etamsylate), menometrorrhagia o Doxium® (calcium dobesilate), diabetic retinopathy o Uro-Vaxom® (immunoactive Escherichia coli extract), recurrent urinary tract infection
Across the Group there are manufacturing and R&D sites in Switzerland and Portugal. Raw materials are sourced globally with active pharmaceutical ingredients manufactured in Switzerland, Germany and Austria. Final products are manufactured by partners across Europe, Turkey and North America. Own and licensed products (products that have a marketing authorization and are commercialized by any Vifor Pharma Group company in at least one country):
Product name Product type
Ferinject®/Injectafer® Ferric carboxymaltose is a high-dose, non- dextran-based intravenous (i.v.) iron
Mircera® Methoxy polyethylene glycol-epoetin beta is a long-acting erythropoiesis-stimulating agent (ESA)
Venofer® Intravenous (i.v.) iron sucrose
RetacritTM Epoetin alfa-epbx is a short-acting ESA
Invokana® Sodium-glucose co-transporter 2 (SGLT2) inhibitor
Velphoro® Polynuclear Iron (III)-Oxyhydroxide, Sucroferric Oxyhydroxide is a non-calcium, iron-based, chewable phosphate binder
Veltassa® Patiromer is a non-absorbed cation-exchange polymer that acts as a potassium binder in the gastro-intestinal tract. Maltofer® Oral iron polymaltose complex (IPC)
Broncho-Vaxom® An extract of different bacterial species used for the treatment and prevention of recurrent respiratory infections Uro-Vaxom® An extract of the bacterium Escherichia coli for the treatment and prevention of recurrent urinary tract infections Doxium® Calcium dobesilate is used for the oral treatment of diabetic retinopathy, signs of chronic venous insufficiency in the lower limbs (pain, cramps, paraesthesia, oedema, stasis dermatosis) and haemorrhoidal syndrome.
Products in development
Product name Product type Vadadustat An oral, investigational hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor Rayaldee® An orally administered, extended-release formulation of calcifediol, a prohormone of the active form of vitamin D3 Avacopan A selective inhibitor of the complement C5a receptor1 (C5aR1) CCX140 An orally administered small molecule that is a selective inhibitor of the chemokine receptor CCR2 CR845 An itch and inflammation suppressant VIT-2763 An oral ferroportin inhibitor
History
CURRENT CONTENT The company was founded in 2008. Vifor Pharma was a result of the acquisition of the former Aspreva Pharmaceuticals.[4] Under this umbrella, the former pharmaceutical companies of Galenica – Vifor (International), Vifor and Potters – were merged into a fully integrated pharmaceutical company. In September 2009, Galenica acquired OM Pharma, a pharmaceutical company active in the field of immunology.[5] The US company Relypsa was taken over by Galenica in September 2016[6] and integrated into Vifor Pharma.[7]
PROPOSED CONTENT • In 1872, Caspar Friedrich Hausmann founds a pharmacy in St. Gallen • In 1927, 16 pharmacists establish a joint purchasing centre, Collaboration Pharmaceutique SA, which went on to be renamed Galenica AG in 1933 (later to be renamed Vifor Pharma Ltd. in 2017) • In 1944, The pharmacist René Grosclaude founds Vifor Ltd; the company produces over-the-counter medicines • In 1983, Hausmann AG laboratories is acquired by Galenica • In 1991, Vifor (International) Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products. • In 2008, Vifor Pharma is founded following the $915 million acquisition of a Canadian company, Aspreva Pharmaceutical Corporation[iv]. Vifor Ltd. and Vifor (international) Ltd. are integrated in Vifor Pharma. • In 2009, Galenica acquires OM Pharma, a Swiss biotechnology company • In 2010, Vifor Pharma Group and Fresenius Medical Care found the joint company Vifor Fresenius Medical Care Renal Pharma (VFMCRP) • In 2014, Galenica is divided into two divisions, Vifor Pharma and Galenica Santé • In 2016, Relypsa, a US based biotechnology company, is purchased for $1.53 billion[V] • In 2017, the IPO of Galenica Santé (GALE) is completed and listed on the Swiss Stock Exchange. Galenica AG (GALE) and Vifor Pharma AG (VIFN) are listed as independent entities since. • In 2019, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) received the Swiss Success Award from the non-profit organisation Swiss Biotech Association[Vi]
References
CURRENT CONTENT
1. "Galenica Santé gut gestartet". Neue Zürcher Zeitung. 7 April 2017. Retrieved 5 October 2017. 2. "Who we are". Vifor Pharma. Retrieved 20 December 2019. 3. "Annual Report 2017" (PDF). Vifor Pharma. Retrieved 20 December 2019. 4. "Galenica says to offer $915 million for Aspreva". Reuters. 18 October 2007. Retrieved 5 October 2017. 5. "Galenica acquiert la société biotech OM Pharma". Le Temps. 8 September 2009. Retrieved 5 October 2017. 6. Sylwia Lasek, Ben Hirschler (21 July 2016). "Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split". Reuters. Retrieved 5 October 2017. 7. "Geschichte". Vifor Pharma. Retrieved 5 October 2017.
PROPOSED CONTENT
iii. https://www.efpia.eu/about-us/membership/
iv. https://www.reuters.com/article/us-galenica-aspreva-idUSL1833840120071018
v. https://www.reuters.com/article/us-relypsa-m-a-galenica-idUSKCN1010I5